Recently a novel article about complement inhibitor treatment discontinuation was published. Novel because of the research method used to produce its results. A qualitative study based on interviews with ten…
The aHUS patient community asked in its research agenda what are the numbers of aHUS patients. Global Action has written about this question a lot over the years , trying…
There are now licensed biosimilars to eculizumab available in Europe and also in the USA ( see previous article and further FDA announcement). Biosimilars can be made available once the…
Our aHUS Alliance Global Action team takes to heart our mission to “Inform. Connect. Collaborate” on ideas and initiatives across all areas of interest to the atypical HUS community. Here’s…
Our aHUS Alliance Global Action team takes to heart our mission to “Inform. Connect. Collaborate” on ideas and initiatives across all areas of interest to the atypical HUS community. Here’s…
On the 10th anniversary of international aHUS awareness day it is timely to raise awareness that the old term aHUS is on its last legs and is to be replaced.…
Every year since the first aHUS Awareness Day on 24 Sept 2015 we’ve attempted to shine a spotlight on atypical HUS research to help add more visibility to (and for)…
The Global Action website has been featuring the pioneers and first events of aHUS history in its series Before aHUS Endeavours Fade. We have featured the work of Professor Conrad…